Compare BANL & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANL | IRIX |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 18.2M |
| IPO Year | 2022 | 1996 |
| Metric | BANL | IRIX |
|---|---|---|
| Price | $0.45 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 414.4K | 143.2K |
| Earning Date | 04-17-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,593,000.00 |
| Revenue This Year | N/A | $3.07 |
| Revenue Next Year | N/A | $6.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $0.87 |
| 52 Week High | $1.09 | $1.65 |
| Indicator | BANL | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 40.79 |
| Support Level | $0.40 | $1.01 |
| Resistance Level | $0.47 | $1.18 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 34.88 | 42.86 |
CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.